Neuroblastoma: validation of the INRG classification system in a small series

• E. Ramos Elbal ^[1] ; A. M. Galera Miñarro ^[1] ; M. E. Llinares Riestra ^[1] ; M. Bermúdez Cortés ^[1] ; J. L. Fuster Soler ^[1]
  1. [1] Hospital Virgen de la Arrixaca

     Hospital Virgen de la Arrixaca

     Murcia, España

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 12 (December), 2019, págs. 1776-1780
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose In 2009, the International Neuroblastoma Risk Group (INRG) published a new classification system of the childhood neuroblastic tumors. In this work, we present the results of the application of this new classification system in our patients.

    Methods/patients We conducted a retrospective analysis of the patients diagnosed with a neuroblastic tumor in our center in the last 20 years. We classified them according to the new classification and performed a survival analysis based on the Kaplan–Meier method and Mantel–Cox test.

    Results The five-year event-free survival (5-year EFS) was 95.8, 80.8, 50 and 45.9% for the very low, low, intermediate and high-risk groups. Mantel–Cox test showed statistically significant differences between these risk groups (p = 0.002).

    Conclusion The 5-year EFS for the different risk groups was similar to the expected by the INRG. Therefore, this classification allows us to predict the evolution of this tumor and apply the correct intensity of treatment.